---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-315896"
form_type: "8-K"
ticker: "KMTS"
cik: "0001877184"
company_name: "KESTRA MEDICAL TECHNOLOGIES, LTD."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:32:48.452579+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kestra Q2 FY26 revenue $22.6M (+53% YoY); guides FY26 to $91M (+52% YoY)

## Summary
- Gross margin expanded to 50.6% from 39.6% YoY, driven by volume leverage and a higher mix of in-network patients.
- GAAP net loss $32.8M; adjusted EBITDA loss $19.7M vs $16.1M prior year.
- Prescriptions for ASSURE system grew 54% YoY to 4,696; revenue benefited from market share gains and WCD market expansion.
- Raised FY26 revenue guidance to $91M (52% growth); cash $175M at Oct 31 (excl. $148M net from subsequent equity offering).
- CEO cites strong commercial momentum, positive post-approval study data, and balance sheet fortification.

## SEC filing metadata
- accession: 0001193125-25-315896
- form_type: 8-K
- ticker: KMTS
- cik: 0001877184
- company_name: KESTRA MEDICAL TECHNOLOGIES, LTD.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1877184/000119312525315896/0001193125-25-315896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1877184/000119312525315896/ck0001877184-20251211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-315896
- JSON: https://secwatch.observer/filing/0001193125-25-315896.json
- Plain text: https://secwatch.observer/filing/0001193125-25-315896.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.